百济神州首次实现季度GAAP盈利一季度泽布替尼全球销售额超50亿元

动脉网
07 May

百济神州在2025年第一季度实现首次GAAP季度盈利,营收达80.48亿元,同比增长50.2%。核心产品泽布替尼全球销售额突破56.92亿元,其中在美国市场销售额达到40.41亿元,同比增长61.9%,并成为美国CLL和BTK抑制剂市场的领导者。公司预计全年营业收入将介于352亿元至381亿元之间,并重申经营利润为正且经营活动产生现金流为正。此外,百济神州在全球六大洲的业务布局进一步加强,展示了其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10